Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration

Inclusion Criteria: 1. ability to provide written informed consent and comply with study assessments for the full duration of the study; 2. age \>40 years; 3. presence of treatment-naïve neovascular AMD with a visual acuity between 20/25 and 20/200 on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart. Inclusion criteria for AMD were neovascularisation, fluid, or haemorrhage under the fovea. Exclusion Criteria: 1. any previous intravitreal treatment; 2. previous laser treatment in the study eye; 3. myopia \>7 dioptres in the study eye; 4. concurrent eye disease in the study eye that could compromise visual acuity (eg, diabetic retinopathy, advanced glaucoma); 5. concurrent corneal epithelial disruption or any condition that would affect the ability of the cornea to heal; 6. known sensitivity to any component of the formulations under investigation.